title: Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study.
abstract: Extranodal natural killer (NK)/T cell lymphoma, nasal type, is a recently recognized distinct entity and the most common type of non-B cell extranodal lymphoma in Asia. This retrospective analysis studied the potential survival benefits of hematopoeitic stem cell transplantation (HSCT) compared with a historical control group. A total of 47 patients from 3 previously published series of HSCT were matched according to NK/T cell lymphoma International Prognostic Index (NKIPI) risk groups and disease status at transplantation with 107 patients from a historical control group for analysis. After a median follow-up of 116.5 months, the median survival time was not determined for the HSCT group, but it was 43.5 months for the control group (95% confidence interval [CI] = 6.7 to 80.3 months; P = .127, log-rank test). In patients who were in complete remission (CR) at the time of HSCT or at surveillance after remission, disease-specific survival rates were significantly higher in the HSCT group compared with the control group (disease-specific 5-year survival rate, 87.3% for HSCT vs 67.8% for non-HSCT; P = .027). In contrast, in subgroup analysis on non-CR patients at the time of HSCT or non-HSCT treatment, disease-specific survival rates were not significantly prolonged in the HSCT group compared with the control group (1-year survival rate, 66.7% for HSCT vs 28.6% for non-HSCT; P = .141). The impact of HSCT on the survival of all patients was significantly retained at the multivariate level with a 2.1-fold (95% CI =1.2- to 3.7-fold) reduced risk of death (P = .006). HSCT seems to confer a survival benefit in patients who attained CR on postremission consolidation therapy. These findings suggest that, in particular, patients in CR with high NKIPI risk scores at diagnosis should receive full consideration for HSCT.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jeeyun
authors.initials: J
authors.lastname: Lee
authors.forename: Wing-Yan
authors.initials: WY
authors.lastname: Au
authors.forename: Min Jae
authors.initials: MJ
authors.lastname: Park
authors.forename: Junji
authors.initials: J
authors.lastname: Suzumiya
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Kameoka
authors.forename: Chikara
authors.initials: C
authors.lastname: Sakai
authors.forename: Kazuo
authors.initials: K
authors.lastname: Oshimi
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
authors.forename: Raymond
authors.initials: R
authors.lastname: Liang
authors.forename: Harry
authors.initials: H
authors.lastname: Yiu
authors.forename: Kam-Hung
authors.initials: KH
authors.lastname: Wong
authors.forename: Hoi-Ching
authors.initials: HC
authors.lastname: Cheng
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Young Hyeh
authors.initials: YH
authors.lastname: Ko
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Jae-Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
mesh_terms: D000293:Adolescent; D000368:Aged; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005202:Asia, Eastern; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D014182:Transplantation, Autologous